ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5).

We dedicate this manuscript in memory of a dear friend and colleague Bella Kaufman. The fifth International Consensus Symposium for Breast Cancer in Young Women (BCY5) took place virtually in October 2020, organized by the European School of Oncology (ESO) and the European Society of Medical Oncology (ESMO). Consensus recommendations for the management of breast cancer in young women were updated from BCY4 with incorporation of new evidence to inform the guidelines. Areas of research priorities as well as specificities in different geographic and minority populations were identified. This manuscript summarizes the ESO-ESMO international consensus recommendations, which are also endorsed by the European Society of Breast Specialists (EUSOMA).
Competing Interests: Disclosure SPS: Advisory Board consultancy, speaker's bureau: AstraZeneca, Pfizer, Novartis, Lilly, Roche, MSD, Exact Sciences. Research Funding: Pfizer. HAA: Recipient of grants/research supports: Amgen. Recipient of honoraria or consultation fees: Novartis, Roche. Employment: Pierre Fabre. FC: Recipient of honoraria or consultation fees: Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, GlaxoSmithKline, Macrogenics, Medscape, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, prIME Oncology, Roche, Samsung Bioepis. GC: Recipient of grants/research supports: Merck, Astra Zeneca. Recipient of honoraria or consultation fees: Daichii Sankyo. Participation in a sponsored speakers’ bureau: Novartis, Pfizer, Lilly. KAG: Recipient of grants/research supports: Pfizer, Astra Zeneca. Recipient of honoraria or consultation fees: Pfizer, Lilly, Astrazeneca, Novartis, Mylan, Benentech, Merck, Roche, Nanostring. NH: Honoraria for lectures and/or consulting from Amgen, Astra Zeneca, Daiichi-Sankyo, Exact Sciences, Lilly, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Sandoz, Seagen (all outside the submitted work). SBK: Research funding from Novartis, Sanofi-Aventis and DongKook Pharm Co; consultant in advisory boards—Novartis, AstraZeneca, Lilly, Dae Hwa Pharmaceutical Co. Ltd, ISU Abxis, Daiichi-Sankyo and Beigene; and stocks—Genopeaks, NeogeneTC (all outside the submitted work). FP: Recipient of honoraria or consultation fees: Roche Diagnostics, Ipsen, Merck (all outside the submitted work). ES: Recipient of grants/research supports: Amgen, AstraZeneca, Boehringer, Eli Lilly, Merck, Novartis, Pfizer, Roche, Samsung. Recipient of honoraria or consultation fees: Amgen, AstraZeneca, Clinigen, Egis, Eli Lilly, Genomic Health, Novartis, Pfizer, Pierre Fabre, Roche, Sandoz, TLC Biopharmaceuticals. Travel support: Amgen, AstraZeneca, Egis, Novartis, Pfizer, Roche. All other authors have declared no conflicts of interest.
(Copyright © 2022 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved.)